Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARGX-110 + Azacytidine in Newly Diagnosed AML/MDS
NCT03030612Phase 2Completed
- Sponsor
- OncoVerity
- Start
- Dec 2016
- Primary completion
- Aug 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of cusatuzumab in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by OncoVerity. Started Dec 2016; status: completed.
02
Drugs
cusatuzumab
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03030612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03030612.